Group 1 - The company has decided to cancel the supervisory board and amend its articles of association in accordance with the new Company Law and relevant regulations [6][35][36] - The board meeting held on August 26, 2025, approved the proposal to cancel the supervisory board, which will be replaced by the audit committee [6][35][36] - The company will adjust its registered capital from 940,093,188 yuan to 933,786,584 yuan following the cancellation of the supervisory board [7][36] Group 2 - The company plans to apply for a total of 4.2 billion yuan in comprehensive credit facilities from various banks to support its business operations [14] - The company reported that as of June 30, 2025, it has not utilized any of the raised funds, with a remaining balance of approximately 1.99 billion yuan [17] - The supervisory board has reviewed the company's half-year report and confirmed that it complies with all legal and regulatory requirements [31][32]

■■■■■ 经上述修改后，《公司章程》的条款编号及引用前文条款编号等作相应调整，《公司章程》其他条款不 变。 公司股东会授权总经理办理变更登记的相关手续。 上述议案还须提交股东会审议，股东会以特别议案表决通过。 特此公告。 中国软件与技术服务股份有限公司董事会 2025年8月27日 证券代码： 600536 证券简称： 中国软件 公告编号：2025-044 二、募集资金存放和管理情况 中国软件与技术服务股份有限公司关于2025 半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 根据中国证券监督管理委员会《关于同意中国软件与技术服务股份有限公司向特定对象发行股票注册的 批复》（证监许可〔2025〕1229号），公司向特定对象发行股票90,130,689股，募集资金总额为人民币 1,999,999,988.91元，扣除发行费用（不含增值税）人民币6,913,613.79元，实际募集资金净额为人民币 1,993,086,375 ...

Fundraising Overview - The company raised a total of RMB 77,773.50 million by issuing 31.5 million shares at RMB 24.69 per share, with a net amount of RMB 70,478.17 million after deducting various fees [2][3] - As of June 30, 2025, the remaining balance of the raised funds was RMB 812.75 million [3] Fund Management and Usage - The company established a management system for the raised funds, ensuring they are stored in dedicated bank accounts and managed according to relevant laws and regulations [4][5] - Two fundraising accounts have been fully utilized and subsequently closed as of June 30, 2025 [7] Fund Usage Details - The company used part of the raised funds to permanently supplement working capital, amounting to RMB 27.50 million [8] - No idle funds were used for cash management during the reporting period [8] Asset Impairment Provision - The company approved an asset impairment provision totaling RMB 9,334,662.68 for the first half of 2025, reflecting a cautious approach to financial reporting [18][19] - This provision will reduce the company's profit for the reporting period but will not affect cash flow [18] Board and Supervisory Committee Resolutions - The board and supervisory committee unanimously approved the half-year report and the asset impairment provision, confirming compliance with relevant regulations [36][50]

Core Viewpoint - The report outlines the fundraising activities and the management of raised funds by the company, ensuring compliance with relevant regulations and highlighting the effective use of funds for investment projects. Fundraising Overview - The company raised a total of RMB 200,345.04 million through the issuance of 26.67 million shares at RMB 75.12 per share, with a net amount of RMB 183,362.57 million after deducting issuance costs of RMB 16,982.47 million [1][18]. - As of June 30, 2025, the company has utilized RMB 138,177.92 million of the raised funds, including RMB 15,950.33 million for replacing pre-invested funds [2]. Fund Management and Storage - The company adheres to strict regulations for managing and using the raised funds, ensuring the protection of stakeholders' rights [3][4]. - A tripartite supervision agreement was signed with the sponsor and banks to oversee the management of the funds [3]. Fund Usage - In the first half of 2025, the company used RMB 182.57 million of the raised funds, bringing the total usage to RMB 138,360.49 million, all allocated to investment projects [6][8]. - There were no changes in the implementation location or method of the investment projects as of June 30, 2025 [7]. Pre-investment and Replacement - Prior to the actual arrival of the raised funds, the company invested RMB 16,425.87 million from its own funds, with RMB 15,950.33 million later replaced by the raised funds [8]. Idle Funds Management - There were no instances of using idle funds to temporarily supplement working capital or for cash management in the first half of 2025 [9][10]. Surplus Funds - Surplus funds from completed projects were permanently transferred to the company's general account for working capital [11][12]. Unused Funds - As of June 30, 2025, the company had RMB 174.03 million of unused raised funds, all stored in dedicated accounts [13]. Project Changes - There were no changes to the fundraising investment projects as of June 30, 2025 [15]. Compliance and Reporting - The company has complied with all relevant regulations regarding the storage, usage, and management of raised funds, with no violations reported [16].

Fundraising Overview - The company raised a total of RMB 595.95 million through the issuance of 27.4 million shares at a price of RMB 21.75 per share, with a net amount of RMB 560.19 million after deducting issuance costs [1] - As of June 30, 2025, the company has utilized RMB 585.12 million of the raised funds, leaving a balance of RMB 5.13 million [2] Fund Management and Usage - The company has established a fundraising management system in compliance with relevant laws and regulations, ensuring that funds are stored in dedicated accounts and used specifically for designated projects [3] - A tripartite supervision agreement was signed with several banks to oversee the management and usage of the raised funds [4][5] - The company has not used idle funds for temporary working capital or cash management during the reporting period [7][8] Investment Projects - The company has made adjustments to some fundraising investment projects to improve efficiency, which were disclosed in a timely manner [5] - As of June 30, 2025, there were no pre-investments or replacements of funds for investment projects [6][9] Profit Distribution - The company proposed a cash dividend of RMB 1.50 per 10 shares, totaling approximately RMB 21.71 million, which represents 68.89% of the company's net profit for the first half of 2025 [15][18] Overseas Investment - The company plans to invest up to USD 20.5 million in building a production base in Vietnam to enhance its international competitiveness and optimize its global strategic layout [24][28] - The investment aims to improve supply chain resilience and reduce tariff costs, responding to changes in the trade environment [29][30] Audit Firm Appointment - The company intends to reappoint Rongcheng Certified Public Accountants as its auditor for the year 2025, pending approval from the upcoming shareholders' meeting [33][46]

Core Points - The company raised a total of $70,000,049.00 from the issuance of Global Depositary Receipts (GDRs), equivalent to approximately ¥502,355,351.65, after deducting related expenses [1] - As of June 30, 2025, the company has utilized ¥145,687,079.58 of the raised funds [5] - The company has established a dedicated management system for the raised funds, ensuring they are stored in special accounts and used according to regulations [3] Fundraising Overview - The GDR issuance consisted of 7,438,900 units at a price of $9.41 each, corresponding to 37,194,500 shares of A-shares [1] - The net amount raised after expenses was approximately ¥476,598,996.87 [1] Fund Usage and Management - The company has not changed the implementation location or method for any fundraising projects during the reporting period [5] - There were no instances of using idle funds for temporary working capital or cash management [5] - As of June 30, 2025, there remains ¥25,415,775.74 of unutilized funds, including interest income [5] Compliance and Reporting - The company has confirmed that there are no violations in the management of the raised funds and that all disclosures have been made in accordance with regulatory requirements [6][11] - The special report on the use of raised funds was approved by the board on August 27, 2025 [6][11]

Fundraising Overview - The company raised a total of RMB 845.65 million from its initial public offering, with a net amount of RMB 778.11 million after deducting underwriting and other related fees [1][2] - As of June 30, 2025, the company had a remaining balance of RMB 83.02 million in its fundraising account, which includes interest income [2][3] Fund Management - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests, including a tripartite supervision agreement with banks [3][4] - The company has not used any of the raised funds for supplementing working capital or for cash management during the reporting period [7][8] Fund Utilization - The company has utilized RMB 133.24 million of the raised funds to replace self-raised funds previously invested in fundraising projects [6] - The company has not used any surplus funds for ongoing or new projects during the reporting period [10][11] Legal Matters - The company is involved in several lawsuits with a cumulative amount of RMB 220.62 million, which represents 22.69% of its latest audited net assets [23][24] - Key cases include disputes over project payments and a stock acquisition agreement, with ongoing legal proceedings [25][26][27] Board Changes - The company has appointed a new non-independent director, Sun Wei, and a new board secretary, He Yufei, following the resignation of a previous director [35][37] Shareholder Meeting - The company will hold its fourth extraordinary general meeting on September 12, 2025, to discuss various resolutions, including the appointment of new board members [54][56]

Core Viewpoint - The report outlines the fundraising activities and usage of funds by Anhui Huaheng Biological Technology Co., Ltd., detailing the amounts raised, their allocation, and compliance with regulatory requirements [1][2][3]. Fundraising Overview - In 2021, the company raised a total of RMB 625.32 million by issuing 27 million shares at RMB 23.16 each, with a net amount of RMB 559.26 million after deducting issuance costs of RMB 66.06 million [1]. - As of June 30, 2025, the company reported the usage and balance of the funds raised from the 2021 IPO [2]. Fund Usage and Surplus - The company has completed the fundraising projects and decided to permanently supplement working capital with surplus funds from two projects: "5000 tons/year fermentation method for alanine technical transformation expansion project" and "alternating annual production of 25,000 tons of alanine and valine project" [3]. 2022 Fundraising Activities - In 2024, the company raised RMB 699.99 million by issuing 21,122,510 shares at RMB 33.14 each, with a net amount of RMB 683.81 million after deducting issuance costs of RMB 16.19 million [4]. - The funds from the 2022 issuance were also managed under strict regulatory compliance [5][6]. Fund Management - The company has established a fundraising management system to ensure the proper storage, approval, and usage of the raised funds, adhering to relevant laws and regulations [5]. - Specific agreements were signed with banks to ensure the funds are stored in dedicated accounts, ensuring transparency and compliance [6]. Actual Fund Usage - As of June 30, 2025, the company utilized RMB 456.93 million from the 2021 IPO funds and RMB 684.05 million from the 2022 issuance for related projects [7]. - The company has not used idle funds for temporary working capital supplementation or cash management during the reporting period [9][10]. Project Adjustments - In March 2025, the company approved the addition of new products to existing projects, including L-valine and inositol, as well as increasing production capacity for other bio-based products [11]. Compliance and Reporting - The company has complied with all relevant regulations regarding the usage and disclosure of fundraising activities, with no violations reported [13].

Fundraising Overview - The company raised a total of RMB 394,016,730.00 from its initial public offering (IPO) by issuing 38,667,000 shares at RMB 10.19 per share, with a net amount of RMB 347,440,291.00 after deducting issuance costs [1][2] - For the non-public offering, the company raised RMB 499,999,984.00 at a price of RMB 19.69 per share, resulting in a net amount of RMB 495,954,700.96 after deducting issuance costs [2][3] Fund Management - The company has established a fundraising management method to ensure the proper management and use of raised funds, in compliance with relevant laws and regulations [3][4] - The company has signed tripartite supervision agreements with banks to manage the special accounts for the raised funds [5][8] Fund Usage - As of June 30, 2025, the company has used RMB 346,338,200.00 from the IPO funds and RMB 498,098,300.00 from the non-public offering funds [10][12] - The company has not used any idle funds for temporary working capital or for cash management during the reporting period [11][13] Project Changes - The company has made changes to its fundraising projects, including reallocating unused funds from the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project to new projects [14][15][16] - The company has also approved the completion of certain projects and the permanent allocation of surplus funds to working capital [12][13] Disclosure Compliance - The company has complied with the disclosure requirements set by the China Securities Regulatory Commission, ensuring timely and accurate reporting of the fundraising and usage status [17]

Group 1 - The company raised a total of RMB 384.04 million through its initial public offering, with a net amount of RMB 331.07 million after deducting issuance costs of RMB 52.97 million [24][25]. - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations and protecting investor rights [24][25]. - As of June 30, 2025, the company has not used any idle raised funds to temporarily supplement working capital [7][12]. Group 2 - The company has approved the use of up to RMB 300 million of idle raised funds for cash management, allowing investment in low-risk, liquid financial products [8][9]. - The company has not experienced any changes in the use of raised funds for investment projects during the reporting period [14]. - The company has confirmed that the disclosure of raised funds usage aligns with actual usage, with no violations in storage, usage, or management [15]. Group 3 - The company plans to replace self-raised funds used for investment projects and issuance costs with raised funds, totaling RMB 70.23 million [23][26]. - The company has received verification from the accounting firm regarding the replacement of self-raised funds, confirming compliance with regulations [28][29]. - The board of directors has approved the report on the usage of raised funds and the replacement of self-raised funds [33][36].